ReviewExpert opinion on drug delivery2008
Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy.
Review in Expert opinion on drug delivery, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 55 citations in OpenAlex.
- Dual epigenetic and nuclear export inhibition by chidamide and selinexor in high grade B-cell lymphomas via survivin and PI3K/AKT inhibition.Clinical epigenetics · 2026Article
- Molecular Engineering of Functional SiRNA Agents.ACS synthetic biology · 2024Article
- Principle, application and challenges of development siRNA-based therapeutics against bacterial and viral infections: a comprehensive review.Frontiers in microbiology · 2024Review
- Small interfering RNA (siRNA)-based therapeutic applications against viruses: principles, potential, and challenges.Journal of biomedical science · 2023Review
- Survivin Small Molecules Inhibitors: Recent Advances and Challenges.Molecules (Basel, Switzerland) · 2023Review
- Insights on prospects of nano-siRNA based approaches in treatment of Cancer.Frontiers in pharmacology · 2022Review
- Small interfering RNA for cancer treatment: overcoming hurdles in delivery.Acta pharmaceutica Sinica. B · 2020Review
- A review on current status of antiviral siRNA.Reviews in medical virology · 2018Review
- PLGA-based dual targeted nanoparticles enhance miRNA transfection efficiency in hepatic carcinoma.Scientific reports · 2017Article
- Quantum Dots-siRNA Nanoplexes for Gene Silencing in Central Nervous System Tumor Cells.Frontiers in pharmacology · 2017Article
- Biological effects of RNAi targeted inhibiting Tiam1 gene expression on cholangiocarcinoma cells.International journal of clinical and experimental pathology · 2015Article
- Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Targeted gene silencing using a follicle-stimulating hormone peptide-conjugated nanoparticle system improves its specificity and efficacy in ovarian clear cell carcinoma in vitro.Journal of ovarian research · 2013Article
- Technologies for investigating the physiological barriers to efficient lipid nanoparticle-siRNA delivery.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2013Review
- Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2011Article
- Localized, targeted, and sustained siRNA delivery.Chemistry (Weinheim an der Bergstrasse, Germany) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
RNA interference technology has been developed as a potential therapeutic agent for many indications, including cancer. Silencing a specific oncogene in tumor cells brings about cell death both in vitro and in vivo. However, there is a great need for powerful delivery strategies to enhance the therapeutic effect of small interfering RNA (siRNA). This review summarizes different signaling pathways inhibited by siRNA and the advantages of targeted siRNA as a delivery system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.